Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)
First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and...
Month: December 2022
InnerScope Hearing Technologies (OTC: INND) Launches Its iHEAR Brand of OTC Hearing Aids on CVS.com
InnerScope Launches its iHEAR Brand of Over-the-Counter Rechargeable Hearing Aid Models with Bluetooth Wireless Smartphone Connection and Full Audio Streaming...
Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing...
Carrick Therapeutics Closes Series C Financing
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology pipeline across multiple indications DUBLIN,...
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live moderated panel discussion on Thursday,...
Rapid Micro Biosystems Concludes Review of Strategic Alternatives
LOWELL, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Theriva Biologics to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
Initial CD388 clinical data expected in the first half of 2023SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics,...
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in...
FDA Grants Fast Track Designation to Nuvectis Pharma’s NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
Wishbone Medical Receives Funding From Institutional Investor, Appoints Dr. Mark Figgie as CEO
Strengthened relationship with LKCM Headwater prompts a shift in leadership and refocused business strategyWARSAW, Ind., Dec. 01, 2022 (GLOBE NEWSWIRE)...
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease...
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like...
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Petalfast Welcomes Premium Cannabis Brand Wonderbrett to Growing Sales and Distribution Portfolio
The iconic cannabis and lifestyle brand joins Petalfast’s route-through-market sales platform in California and ArizonaIRVINE, Calif., Dec. 01, 2022 (GLOBE...
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine...
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC)...